CA Patent

CA3078163A1 — Methods of treating heart failure with preserved ejection fraction

Assigned to Poxel SA · Expires 2019-04-11 · 7y expired

What this patent protects

The present invention provides a method for treating or preventing heart failure with preserved ejection fraction (HFPEF), wherein the method comprises administering to a patient having or at risk of developing HFPEF a therapeutically effective amount of imeglimin.

USPTO Abstract

The present invention provides a method for treating or preventing heart failure with preserved ejection fraction (HFPEF), wherein the method comprises administering to a patient having or at risk of developing HFPEF a therapeutically effective amount of imeglimin.

Drugs covered by this patent

Patent Metadata

Patent number
CA3078163A1
Jurisdiction
CA
Classification
—
Expires
2019-04-11
Drug substance claim
No
Drug product claim
No
Assignee
Poxel SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.